HIF1A and Dowling-Degos disease 1: Intraperitoneal (i.p.)administration of 2ME2, a pharmacological Hif1α inhibitor, attenuated mechanical stress-induced DDD pathogenesis, which further shows the harmful role of aberrantly enhanced HIF1α activity in DDD.